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In a registry-based case–control study, we compared the site-specific occurrence of nonmelanoma (keratinocytic) skin cancers
among patients with cutaneous melanoma cases (cases, n¼3774) and solid tumours (controls, n¼349923), respectively. Overall,
patients with melanoma were almost five-fold more likely to develop keratinocytic cancers compared with solid tumour controls
(adjusted OR 4.7, 95% CI 4.1–5.3), but the risks varied depending upon the site of melanoma. Whereas patients with melanoma of
the head and neck had similarly increased risks of keratinocytic cancers across all body sites, patients with melanoma of the trunk
were significantly more likely to develop keratinocyte cancer diagnosed on the trunk (adjusted OR 12.5, 95% CI 7.2–20.2) than on
the head and neck (adjusted OR 3.0, 95% CI 2.2–4.3). Similar colocalisation of skin tumours was observed for patients with
melanomas of the lower limb. These findings provide support for the hypothesis that skin cancers at different anatomical sites may
arise through different causal pathways.
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While there is consensus that sunlight is the principal environ-
mental cause of melanomas, their anatomical distribution
precludes a simple association with sunlight. Some sites (e.g.
trunk) typically have modest levels of sun exposure yet have high
melanoma incidence, whereas other highly exposed sites (e.g.
hand) have lower melanoma incidence (Green et al, 1993; Bulliard
et al, 1997).
One explanation for these observations may be that the causes of
melanoma vary depending upon the anatomical site of the
melanocyte The ‘divergent pathway’ model proposes that the
relative contribution of genetic and environmental exposures
differs according to the anatomic location of the melanoma
(Whiteman et al, 2003).
The association between sunlight and basal cell carcinoma
(BCC) is similarly complex with many lesions occurring on less
sun exposed sites, a plateau of incidence with age and a strong
association between recreational exposure and risk (Kricker et al,
1995). In contrast to melanoma and BCC, the risk of squamous cell
carcinoma (SCC) rises monotonically with exposure to the sun.
Patients with melanoma are known to be at a substantially
increased risk of the nonmelanoma skin cancers (NMSC) BCC and
SCC (Wassberg et al, 1996; Levi et al, 1997a; Hemminki et al, 2003;
Crocetti and Carli, 2004) and the converse is also true (Levi et al,
1997b, 1998; Wassberg et al, 1999; Bower et al, 2000; Maitra et al,
2005). However, it is not known whether the association between
melanoma and NMSC varies according to the anatomical site. We
chose to explore this question using a record-linkage study from
a British cancer registry. We hypothesised that because of shared
risk factors, patients with melanoma of the head or neck would be
at particularly high risk of nonmelanoma skin cancer and
specifically SCCs.
MATERIALS AND METHODS
We conducted a registry-based case–control study to test the
hypothesis that the risk of site-specific NMSC among people with
melanoma varies according to the site of the melanoma. People
with melanoma (cases) were compared with people with a solid
tumour other than melanoma (controls) for the prevalence of
NMSC.
This data-linkage study was conducted using records obtained
from the Northern & Yorkshire Cancer Registry and Information
Service (NYCRIS). Northern & Yorkshire Cancer Registry and
Information Service is responsible for the registration of all
malignant cancers in the former Northern and Yorkshire NHS
regions and covers a population of 6.4 million. This study was
approved by the NYCRIS Advisory Group.
Case selection
Eligible cases were all notifications of invasive melanoma (ICD10
C43) among people aged 15 years and older diagnosed between
January 1986 and December 2000 (99% of diagnoses were
histologically confirmed and melanoma registration is estimated
to be at least 88% complete (Stefoski Mikeljevic et al, 2003). We
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from NMSC. For the primary analysis, we restricted cases to
patients with primary invasive melanoma of the superficial
spreading or nodular histological subtypes. We therefore excluded
patients diagnosed with metastatic melanomas, lentigo maligna
melanomas and rare histological subtypes of melanoma that have
not been associated with sun exposure (e.g. acral lentiginous
melanoma, desmoplastic melanoma, spindle cell melanoma, etc.)
and those without a histological subtype.
Control selection
Controls were all people diagnosed with a nonskin solid tumour
(ICD 10 codes C00-C75, excluding C43-C44) and diagnosed during
the same time interval as the cases. We excluded controls
diagnosed with more than one tumour (apart from NMSC) during
the study interval, and those who had a diagnosis in childhood
(ageo15 years).
Data collection
Age and sex of cases and controls were captured from the registry
records, as well as the date of diagnosis and site of melanoma or
other solid tumour where available. Notifications of cancers were
ascertained from pathology reports, medical records of National
Health Service and independent hospitals and hospices and death
certificates. An examination of completeness of NYCRIS skin
cancer registration in 1994 demonstrated that 83% of NMSC were
captured (Stefoski Mikeljevic et al, 2003).
NYCRIS staff routinely check all new registrations to link second
(or subsequent) cancers occurring in previously registered
patients. A match is made on the basis of name, date of birth
and postcode of address where possible. Where there are common
alternative spellings or abbreviations for a name these are also
explored. If a patient has already been registered, the site and type
of tumour is examined to determine if the new tumour is a new
primary or represents additional information regarding a previous
registration. Where the sites are different, a new registration is
made. If the sites are the same, the pathological type of tumour is
examined – the same type is not reregistered unless there is explicit
evidence that there is a new primary. This routine linkage
information was used to identify occurrence of NMSC (ICD10
C44) (specifically BCC, SCC and carcinoma in situ (CIS)) among all
melanoma cases and other solid tumour controls.
Statistical analysis
The primary aim of this analysis was to compare the prevalence of
NMSC among patients with melanoma and other solid tumours,
and to compare the magnitude of the associations according to
the anatomical site of the melanoma. We therefore categorised
melanoma cases into those whose melanoma occurred on the
trunk, the head and neck, the upper limbs and the lower limbs
and compared each group of cases to the control series. For this
analysis, we were interested in the occurrence of all NMSC; hence,
there was no reason a priori to specify whether the event of NMSC
occurred before or after the event of melanoma or solid tumour
diagnosis. We therefore calculated the odds ratio (OR) and
95% confidence interval (95% CI) to estimate the strength of
association between period prevalence of NMSC and site of
melanoma. The OR disregards any temporal relationship between
the lesions. We calculated the OR using multivariable polytomous
logistic regression with patients having tumours other than
melanoma serving as the reference group. If more than one type
of NMSC was registered for a patient (e.g. one BCC and one SCC),
then we included each type in the respective NMSC type-specific
analysis. If more than one NMSC of the same type was recorded,
then only one of these contributed to the analysis.
In all models we adjusted for sex and age (in single years) at
diagnosis of melanoma (for cases) or solid tumour (for controls),
and we also included an age-squared term to adjust for residual
nonlinear effects of age. All analyses were performed with SAS
software (release 8.2; SAS Institute, Cary, NC, USA).
RESULTS
We identified 349923 control patients who had one tumour other
than melanoma diagnosed between 1 January 1986 and 31
December 2000. The most commonly diagnosed tumours were
those of the breast (ICD10 C45) and colon/rectum/anus (ICD10
C18-C21), each of which accounted for 14% of the registered
tumours. The mean age of diagnosis was 69 years (range 15–111)
and 50% of patients were male (Table 1).
There were 7084 case patients notified with cutaneous
melanoma during the study period. After excluding those with
incomplete notifications (missing anatomical site 491, missing
histological type 2311) or ineligible histological types (LMM 279,
other 229), there were 3774 patients with invasive melanomas with
known site and eligible histological subtype (53% of total) for the
primary analysis. Median age at melanoma diagnosis was 54 years,
but was significantly higher for people with melanoma of the head
and neck (69 years) compared to people with melanomas of the
trunk, upper or lower limbs (53 years) (Po0.001, Wilcoxon test).
The overall prevalence of NMSC was 7% among melanoma cases
and 3% among other solid tumour controls (crude OR 2.5, 95% CI
2.2–2.8). Adjusting for sex and the linear and nonlinear effects of
age substantially increased the OR (adjusted OR 4.7, 95% CI 4.1–
5.3). Among melanoma cases with NMSC, 68% were BCCs, 16%
were SCCs and 16% were CIS. In contrast, among controls with
Table 1 Descriptive statistics for melanoma cases and solid tumour
controls
Cases All melanomas
a Eligible melanomas
b
Head and neck
N (%) of all melanomas 1193 (19) 512 (14)
N (%) female 632 (53) 268 (52)
Mean (median) age at diagnosis 67 (71) 64 (69)
N (%) with keratinocyte cancers 146 (12) 64 (13)
Trunk
N (%) of all melanomas 1550 (24) 1018 (27)
N (%) female 593 (38) 386 (38)
Mean (median) age at diagnosis 52 (53) 52 (53)
N (%) with keratinocyte cancers 97 (6) 65 (6)
Upper limbs
N (%) of all melanomas 1189 (19) 749 (20)
N (%) female 765 (64) 487 (65)
Mean (median) age at diagnosis 54 (54) 53 (52)
N (%) with keratinocyte cancers 79 (7) 55 (7)
Lower limbs
N (%) of all melanomas 2432 (38) 1495 (40)
N (%) female 1944 (80) 1205 (81)
Mean (median) age at diagnosis 55 (55) 53 (53)
N (%) with keratinocyte cancers 142 (6) 92 (6)
Controls
Solid tumours
N 349923
N (%) female 173795 (50)
c
Mean (median) age at diagnosis 69 (70)
N (%) with keratinocyte cancers 10754 (3)
aExcluding those for whom site was unknown.
bSite known, eligible histological type
(not LMM, acral lentiginous, desmoplastic or other ineligible types).
cSex missing for
151 patients.
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SCCs and only one patient was diagnosed with CIS.
Associations between NMSC and melanomas at each anatomical
site are presented in Table 2. On crude analysis, NMSC were more
strongly associated with melanomas of the head and neck (OR 4.5)
than melanomas of the trunk, arms or legs (ORs 2.1–2.5) (Table 2).
After tightly adjusting for age and sex, however, patients with
melanomas at all sites were approximately five-fold more likely to
be diagnosed with NMSC than controls, with little variation in the
magnitude of associations by anatomical site of melanoma. Similar
associations were observed when analyses were restricted to
specific types of NMSC (Table 2).
Further analyses of the body site distribution of NMSC and
melanomas provided some evidence for anatomical colocalisation
of these different types of skin cancer (Table 3). This was most
apparent on the trunk, whereby patients with melanomas of the
trunk were significantly more likely to have an NMSC diagnosed
on the trunk (adjusted OR 12.5, 95% CI 7.2–20.2) or upper limb
(adjusted OR 9.8, 95% CI 4.8–19.8) than the head and neck
(adjusted OR 3.0, 95% CI 2.2–4.3). Similar patterns of colocalisa-
tion of NMSC, particularly BCCs, were observed for patients with
melanomas on the upper and lower limbs. The risk of NMSC in
melanoma patients at sites other than those where the melanoma
arose (with the exception of the trunk and upper limb where both
sites experienced a marked elevation of risk in the presence of
melanoma at either site) was consistently about four-fold higher
than the risk of NMSC in patients with other solid tumours.
DISCUSSION
This study confirms that people with a diagnosis of melanoma
have substantially higher risks of NMSC compared to patients with
other types of cancer. This strong association was not unexpected
and is similar in magnitude to risks reported in other European
record linkage studies (Wassberg et al, 1996; Levi et al, 1997a;
Kroumpouzos et al, 2000; Hemminki et al, 2003; Crocetti and Carli,
2004).
Our a priori hypothesis that patients with melanomas of the
head and neck would have higher overall occurrence of NMSC
than patients with melanomas of the trunk was only partially
supported by these data. On crude analysis, patients with
melanomas of the head and neck had substantially larger
associations with NMSC than patients with melanomas at other
body sites. After adjusting for linear and nonlinear effects of age,
the associations between NMSC and melanoma at all body sites
became markedly stronger and the apparent discrepancy between
melanomas at different sites was removed.
The effects of adjusting for age were considerable; yet
interpreting these effects is not straightforward. Two explanations
may be considered. On the one hand, the analyses could indicate
that the relationship between melanoma and NMSC was negatively
confounded by age. Alternatively, if age is a necessary causal factor
in the development of head and neck melanomas, as suggested
by the more than 10 year age difference between patients with
melanoma of the head and neck vs the trunk in this data set and
others (Elwood and Gallagher, 1998; Bulliard, 2000), then by
adjusting for age, we may actually have introduced bias to the risk
estimates (Hernan et al, 2002). This issue cannot be resolved by
further interrogation of these data.
Our new finding of colocalisation of melanoma and BCC at sites
other than the head and neck has not been previously reported. To
our knowledge, only one other study has investigated this
possibility, although it was hampered by a short duration of
follow-up and a small sample size calling the observed null result
into question (Kroumpouzos et al, 2000). Assuming that our
finding was not the result of chance, the question arises as to why
melanomas and BCC should tend to arise on the same anatomical
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yTable 3 Odds ratio (and 95% CI) of keratinocyte cancers occurring at specific anatomic sites among cases with melanoma of the head/neck, trunk, upper and lower limbs compared to controls with
other solid tumours
Controls
(N¼349923)
Head and neck melanoma cases
(N¼512)
Trunk melanoma cases
(N¼1018)
Upper limb melanoma cases
(N¼749)
Lower limb melanoma cases
(N¼1569)
Keratinocytic
cancer site % % OR (95% CI)
a Adj OR (95% CI)
b % OR (95% CI)
a Adj OR (95% CI)
b % OR (95% CI)
a Adj OR (95% CI)
b % OR (95% CI)
a Adj OR (95% CI)
Head and neck
All keratinocyte
cancers
2.46 10.35 4.58 (3.44–6.09) 5.33 (3.97–7.14) 3.44 1.41 (1.01–1.98) 3.03 (2.15–4.27) 4.14 1.71 (1.19–2.45) 3.68 (2.55–5.31) 2.74 1.12 (0.82–1.53) 2.40 (1.75–3.29)
BCC only
d 2.15 9.49 4.77 (3.53–6.44) 5.58 (4.10–7.60) 3.44 1.62 (1.15–2.28) 3.47 (2.45–4.92) 3.34 1.57 (1.05–2.36) 3.36 (2.22–5.08) 2.50 1.17 (0.84–1.62) 2.44 (1.74–3.41)
SCC only
c 0.39 1.97 5.16 (2.66–10.01) 5.89 (3.02–11.51) 0.63 1.62 (0.72–3.62) 3.89 (1.73–8.74) 0.72 1.85 (0.77–4.47) 5.23 (2.15–12.71) 0.28 0.73 (0.27–1.96) 2.32 (0.87–6.24)
Trunk
All keratinocyte
cancers
0.29 0.78 4.03 (1.50–10.82) 4.44 (1.66–11.93) 1.77 9.22 (5.75–14.78) 12.48 (7.15–20.19) 1.34 6.93 (3.70–12.99) 9.87 (5.23–18.61) 0.80 4.14 (2.37–7.35) 6.04 (3.38–10.81)
BCC only
d 0.17 0.88 5.16 (1.92–13.85) 5.81 (2.16–15.62) 1.55 9.90 (5.43–15.24) 12.32 (7.28–20.85) 1.14 6.66 (3.30–13.43) 9.42 (4.64–19.13) 0.78 4.53 (2.49–8.24) 6.48 (3.53–11.90)
SCC only
c 0.03 0.00 N/C N/C 0.21 7.49 (1.84–30.44) 11.94 (2.86–49.92) 0.14 5.14 (0.72–36.95) 9.83 (1.35–71.58) 0.00 N/C N/C
Upper limbs
All keratinocyte
cancers
0.15 0.59 3.95 (1.27–12.27) 4.39 (1.40–13.71) 0.79 5.28 (2.62–10.64) 9.77 (4.81–19.84) 1.07 7.19 (3.56–14.50) 13.76 (6.76–28.00) 0.27 1.79 (0.67–4.79) 3.56 (1.32–9.59)
BCC only
d 0.07 0.00 N/C N/C 0.63 9.66 (4.28–21.79) 15.76 (6.90–36.02) 0.43 6.63 (2.12–20.78) 10.62 (3.35–33.67) 0.14 2.19 (0.54–8.81) 3.45 (0.85–14.08)
SCC only
c 0.09 0.44 5.06 (1.26–20.30) 5.90 (1.46–23.84) 0.10 1.18 (0.17–8.43) 2.67 (0.37–19.11) 0.14 1.62 (0.23–11.58) 4.07 (0.57–29.09) 0.07 0.80 (0.11–5.72) 2.16 (0.30–15.40)
Lower limbs
All keratinocyte
cancers
0.17 0.39 2.27 (0.56–9.11) 2.49 (0.62–10.03) 0.29 1.71 (0.55–5.32) 3.85 (1.23–12.02) 0.40 2.33 (0.75–7.25) 3.85 (1.25–12.02) 1.74 10.24 (6.89–15.21) 14.39 (9.59–21.58)
BCC only
d 0.10 0.22 2.14 (0.30–15.30) 2.47 (0.35–17.66) 0.31 3.03 (0.97–9.44) 6.26 (1.99–19.71) 0.14 1.38 (0.19–9.87) 2.22 (0.31–15.90) 0.92 8.90 (5.11–15.52) 12.07 (6.85–21.25)
SCC only
c 0.07 0.00 N/C N/C 0.00 N/C N/C 0.00 N/C N/C 0.14 1.98 (0.49–7.88) 3.27 (0.81–13.25)
aOdds ratio and 95% confidence interval. The reference group was people with no keratinocyte cancers in each analysis.
bOdds ratio and 95% confidence interval adjusted for exact age (in years), age squared and sex.
cIn total, 9080
people were excluded from the SCC analysis because they had no SCC diagnosis but a diagnosis of another keratinocyte cancers.
dIn total, 1975 people were excluded from the BCC analysis because they had a diagnosis of a
keratinocyte cancer other than BCC. N/C¼not calculated due to a zero cell in the control group.
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ysites. One possibility is heightened awareness or surveillance of the
body site where the first tumour was excised. This possibility is
supported by the frequent diagnosis of in situ keratinocyte
carcinomas among melanoma patients compared with their virtual
absence in controls. Moreover, a recent Australian study has
shown a marked increase in the incidence of BCC on less sun
exposed body sites when active skin screening is undertaken
(Valery et al, 2004).
Although heightened skin cancer surveillance among melanoma
patients might partially explain colocalisation, this phenomenon
may also reflect common variation in the component causes of
both melanoma and BCC arising at different anatomical sites.
As with melanoma, the association between sun exposure and
BCC is complex and is likely to be modified by genetic factors
and the anatomical location of the target cell (Lear et al, 1997a,b;
Ramachandran et al, 2001a,b). For both melanoma and BCC,
those tumours occurring on the head and neck are more likely to
overexpress p53 protein then their truncal counterparts (D’Errico
et al, 1997; Whiteman et al, 1998). Similarly, both melanomas and
BCC arise at considerably older ages on the head and neck than on
the trunk (Ramachandran et al, 2001a). These various observations
support the view that melanomas and BCCs occurring on the trunk
share similar causes, which appear to differ from those required to
induce BCCs and melanomas of the head and neck.
We considered the possibility that our findings may be
influenced by other sources of error. Under-registration of NMSC
is a potential problem, although recent analyses of the NYCRIS
suggest that more than 80% of NMSC are captured in this
population (Stefoski Mikeljevic et al, 2003). Increased surveillance
of melanoma patients may increase the likelihood of diagnosing
NMSC compared with control patients, but there is no reason to
suppose that registration is differentially related to the site of the
melanoma.
Another potential source of error stems from the fact that
almost half of the melanoma notifications to the registry were
excluded from these analyses, mostly due to missing information
about the histological type of melanoma that was considered
important a priori. We tested the effect of this restriction by
reanalysing the data after including all cases with missing
histological information. We found no alteration in the pattern
of results to those reported in the tables.
In conclusion, these data provide support for the notion that
melanomas and BCCs share similar causal factors, but suggest that
the associations between different types of skin cancer differ
according to the anatomical site of the lesion and the age of
the host.
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